Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0.00750267952840288 0.0257234726688102
Stock impact report

EMA advisory group backs Ionis Pharma's inotersen for hATTR [Seeking Alpha]

Ionis Pharmaceuticals, Inc. (IONS) 
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ionispharma.com
Company Research Source: Seeking Alpha
EMA advisory group backs Ionis Pharma's inotersen for hATTRThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts apositive opinion backing approval for Ionis Pharmaceuticals' (NASDAQ:IONS) Tegsedi (inotersen) for the treatment of hereditary transthyretin amyloidosis (hATTR).The specific indication is the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR.A final decision from the European Commission usually takes ~60 days.Click to subscribe to real-time analytics on IONSNow read:Bulletproof Investing Performance Update: Week 27 » Show less Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
IONS alerts

from News Quantified
Opt-in for
IONS alerts

from News Quantified